Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Cardiology in Review|September 4, 2023
Cardiotoxicity of Breast Cancer ChemotherapySacha A Roberts, William H FrishmanJournal of Hip Preservation Surgery|June 2, 2022
The predictive value of self-reported allergies for reoperation after index hip arthroscopySyian Srikumar, Jacob D Feingold, Erica L Swartwout, et al.Orthopaedic Journal of Sports Medicine|November 22, 2021
Failure to Achieve Threshold Scores on Patient-Reported Outcome Measures Within 1 Year Has a Predictive Risk of Subsequent Hip Surgery Within 5 Years of Primary Hip Arthroscopy: A Case-Control StudyJacob D Feingold, Erica L Swartwout, Sacha A Roberts, et al.Journal of Cell Science|March 1, 2018
Aplip1, the Drosophila homolog of JIP1, regulates myonuclear positioning and muscle stabilityAlexander L Auld, Sacha A Roberts, Ciaran B Murphy, et al.Journal of Hip Preservation Surgery|August 11, 2021
Self-reported allergies correlate with a worse patient-reported outcome after hip arthroscopy: a matched control studyErica L Swartwout, Jacob D Feingold, Joshua I Wright-Chisem, et al.Journal of Surgical Oncology|June 5, 2020
Patients who report cording after breast cancer surgery are at higher risk of lymphedema: Results from a large prospective screening cohortCheryl L Brunelle, Sacha A Roberts, Amy M Shui, et al.Physical Therapy|September 15, 2020
Integrating Symptoms Into the Diagnostic Criteria for Breast Cancer-Related Lymphedema: Applying Results From a Prospective Surveillance ProgramCheryl L Brunelle, Sacha A Roberts, Nora K Horick, et al.Cancer|July 27, 2021
Weight loss does not decrease risk of breast cancer-related arm lymphedemaSacha A Roberts, Tessa C Gillespie, Amy M Shui, et al.Annals of Surgical Oncology|June 12, 2021
Subclinical Lymphedema After Treatment for Breast Cancer: Risk of Progression and Considerations for Early InterventionLoryn K Bucci, Cheryl L Brunelle, Madison C Bernstein, et al.Breast Cancer Research and Treatment|March 29, 2019
Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancerKayla M Daniell, Aditya Bardia, Fangdi Sun, et al.Pageof 1